IRVINE, CA, and HERSTAL, BELGIUM – June 26, 2015 – MDxHealth SA (Euronext Brussels: MDXH) announced today, in conformity with article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that further to the capital increase that was completed on Friday, June 26, 2015, its share capital has increased from € 30,191,238.09 to €  35,097,093.09, and its number of issued and outstanding shares has increased from 37,848,490 to 43,998,490 ordinary shares, through the issuance of 6,150,000 new shares.

In addition to the outstanding shares, the total number of existing warrants (whether or not already granted or already vested) on the date of this press release amounts to 2,554,163 warrants which (if exercised) would entitle their holders to 2,683,315 shares with voting rights.

About MDxHealth^®
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 info@mdxhealth.com

Mike Sinclair Halsin Partners UK: +44 20 7318 2955 Cell: +44 7968 022075 msinclair@halsin.com